Advertisement

Molecular and Cellular Characterization of SIRT1 Allosteric Activators

  • Michael B. Schultz
  • Conrad Rinaldi
  • Yuancheng Lu
  • João A. Amorim
  • David A. SinclairEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1983)

Abstract

SIRT1 is an NAD+-dependent lysine deacetylase that promotes healthy aging and longevity in diverse organisms. Small molecule allosteric activators of SIRT1 such as resveratrol and SRT2104 directly bind to the N-terminus of SIRT1 and lower the Km for the protein substrate. In rodents, sirtuin-activating compounds (STACs) protect from age-related diseases and extend life span. In human clinical trials, STACs have a high safety profile and anti-inflammatory activities. Here, we describe methods for identifying and characterizing STACs, including production of recombinant protein, in vitro assays with recombinant protein, and cellular assays based on mitochondrial dynamics. The methods described in this chapter will facilitate this discovery of improved STACs, natural and synthetic, in the pursuit of interventions to treat age-related diseases.

Keywords

Sirtuin SIRT1 Histone deacetylase (HDAC) Deacylase Deacetylase NAD+ Nicotinamide ADP-ribose Aging Longevity Metabolism Epigenetics Histone p53 Mitochondria Membrane potential Reactive oxygen species (ROS) Sirtuin-activating compound (STAC) Resveratrol Allosteric activator Recombinant protein 

Notes

Acknowledgments

We are grateful for support from the Paul F. Glenn Foundation for Medical Research. This work was supported by NIH R37 AG028730, R01 AG019719, R01 DK100263 and R21 DE027490. J.A.A. is recipient of scholarship from the Portuguese national funds via FCT – Fundação para a Ciência e a Tecnologia (PD/BD/114173/2016).

Disclosure: D.A.S. is a founder, equity owner, board member, advisor to, director of, consultant to, investor in and/or inventor on patents licensed to Vium, Jupiter Orphan Therapeutics, Cohbar, Galilei Biosciences, GlaxoSmithKline, OvaScience, EMD Millipore, Wellomics, Inside Tracker, Caudalie, Bayer Crop Science, Longwood Fund, Zymo Research, EdenRoc Sciences (and affiliates Arc-Bio, Dovetail Genomics, Claret Bioscience, Revere Biosensors, UpRNA and MetroBiotech (an NAD booster company), Liberty Biosecurity), Life Biosciences (and affiliates Selphagy, Senolytic Therapeutics, Spotlight Biosciences, Animal Biosciences, Iduna, Immetas, Prana, Continuum Biosciences, Jumpstart Fertility (an NAD booster company), and Lua Communications). D.A.S. sits on the board of directors of both companies. D.A.S. is an inventor on a patent application filed by Mayo Clinic and Harvard Medical School that has been licensed to Elysium Health; his personal royalty share is directed to the Sinclair lab. For more information see https://genetics.med.harvard.edu/sinclair-test/people/sinclair-other.php. Y.L. is an equity owner of Iduna.

References

  1. 1.
    Kaeberlein M, McVey M, Guarente L (1999) The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 13:2570–2580CrossRefGoogle Scholar
  2. 2.
    Satoh A, Brace CS, Rensing N et al (2013) Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab 18:416–430.  https://doi.org/10.1016/j.cmet.2013.07.013CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Imai S, Armstrong CM, Kaeberlein M, Guarente L (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403:795–800.  https://doi.org/10.1038/35001622CrossRefPubMedGoogle Scholar
  4. 4.
    Luo J, Nikolaev AY, Imai S et al (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107:137–148.  https://doi.org/10.1016/S0092-8674(01)00524-4CrossRefPubMedGoogle Scholar
  5. 5.
    Vaziri H, Dessain SK, Ng Eaton E et al (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149–159CrossRefGoogle Scholar
  6. 6.
    Rodgers JT, Lerin C, Haas W et al (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434:113–118.  https://doi.org/10.1038/nature03354CrossRefPubMedGoogle Scholar
  7. 7.
    Yeung F, Hoberg JE, Ramsey CS et al (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369–2380.  https://doi.org/10.1038/sj.emboj.7600244CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Guarani V, Deflorian G, Franco CA et al (2011) Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature 473:234–238.  https://doi.org/10.1038/nature09917CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zhang J (2007) The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J Biol Chem 282:34356–34364.  https://doi.org/10.1074/jbc.M706644200CrossRefPubMedGoogle Scholar
  10. 10.
    Price NL, Gomes AP, Ling AJ et al (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675–690.  https://doi.org/10.1016/j.cmet.2012.04.003CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bonkowski MS, Sinclair DA (2016) Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol 17:679–690.  https://doi.org/10.1038/nrm.2016.93CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hubbard BP, Gomes AP, Dai H et al (2013) Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339:1216–1219.  https://doi.org/10.1126/science.1231097CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Howitz KT, Bitterman KJ, Cohen HY et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191–196.  https://doi.org/10.1038/nature01960CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Baur JA, Pearson KJ, Price NL et al (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342.  https://doi.org/10.1038/nature05354CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Mitchell SJ, Martin-Montalvo A, Mercken EM et al (2014) The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep 6:836–843.  https://doi.org/10.1016/j.celrep.2014.01.031CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Mercken EM, Mitchell SJ, Martin-Montalvo A et al (2014) SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell 13:787–796.  https://doi.org/10.1111/acel.12220CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hausenblas HA, Schoulda JA, Smoliga JM (2015) Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus—systematic review and meta-analysis. Mol Nutr Food Res 59:147–159.  https://doi.org/10.1002/mnfr.201400173CrossRefPubMedGoogle Scholar
  18. 18.
    Krueger JG, Suárez-Fariñas M, Cueto I et al (2015) A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis. PLoS One 10:e0142081.  https://doi.org/10.1371/journal.pone.0142081CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Dai H, Ellis JL, Sinclair DA, Hubbard BP (2016) Synthesis and assay of SIRT1-activating compounds. Meth Enzymol 574:213–244.  https://doi.org/10.1016/bs.mie.2016.01.012CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wegener D, Wirsching F, Riester D, Schwienhorst A (2003) A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem Biol 10:61–68CrossRefGoogle Scholar
  21. 21.
    Pacholec M, Bleasdale JE, Chrunyk B et al (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285:8340–8351.  https://doi.org/10.1074/jbc.M109.088682CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hubbard BP, Sinclair DA (2013) Measurement of sirtuin enzyme activity using a substrate-agnostic fluorometric nicotinamide assay. Methods Mol Biol 1077:167–177.  https://doi.org/10.1007/978-1-62703-637-5_11CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Gomes AP, Price NL, Ling AJ et al (2013) Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155:1624–1638.  https://doi.org/10.1016/j.cell.2013.11.037CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Funk JA, Odejinmi S, Schnellmann RG (2010) SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J Pharmacol Exp Ther 333:593–601.  https://doi.org/10.1124/jpet.109.161992CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ward MW, Rego AC, Frenguelli BG, Nicholls DG (2000) Mitochondrial membrane potential and glutamate excitotoxicity in cultured cerebellar granule cells. J Neurosci 20:7208–7219CrossRefGoogle Scholar
  26. 26.
    Nicholls DG, Ward MW (2000) Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci 23:166–174CrossRefGoogle Scholar
  27. 27.
    Duchen MR (2004) Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Asp Med 25:365–451.  https://doi.org/10.1016/j.mam.2004.03.001CrossRefGoogle Scholar
  28. 28.
    Nicholls DG (2006) Simultaneous monitoring of ionophore- and inhibitor-mediated plasma and mitochondrial membrane potential changes in cultured neurons. J Biol Chem 281:14864–14874.  https://doi.org/10.1074/jbc.M510916200CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Michael B. Schultz
    • 1
  • Conrad Rinaldi
    • 1
  • Yuancheng Lu
    • 1
  • João A. Amorim
    • 1
    • 2
    • 3
  • David A. Sinclair
    • 1
    • 4
    Email author
  1. 1.Department of Genetics, Blavatnik InstitutePaul F. Glenn Center for the Biology of Aging, Harvard Medical SchoolBostonUSA
  2. 2.CNC—Center for Neuroscience and Cell BiologyUniversity of CoimbraCoimbraPortugal
  3. 3.IIIUC—Institute of Interdisciplinary ResearchUniversity of CoimbraCoimbraPortugal
  4. 4.Department of Pharmacology, School of Medical SciencesThe University of New South WalesSydneyAustralia

Personalised recommendations